MCID: MDY006
MIFTS: 33

Mody, Type Iv

Categories: Genetic diseases, Rare diseases

Aliases & Classifications for Mody, Type Iv

MalaCards integrated aliases for Mody, Type Iv:

Name: Mody, Type Iv 54 13
Mody4 12 50 24 71
Mody Type 4 12 50 71
Maturity-Onset Diabetes of the Young, Type 4 50 29
Maturity-Onset Diabetes of the Young Type 4 12 24
Maturity-Onset Diabetes of the Young, Type Iv 69
Maturity-Onset Diabetes of the Young Type Iv 24
Type 4 Maturity-Onset Diabetes of the Young 50
Mody Insulin Promoter Factor-1 Related 50
Maturity-Onset Diabetes of the Young 4 71
Diabetes Mellitus, Mody Type 4 24
Diabetes Mellitus Mody Type 4 50
Mody-4 71

Characteristics:

HPO:

32
mody, type iv:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 54 606392
Disease Ontology 12 DOID:0111103
MedGen 40 C1833382
MeSH 42 D003924

Summaries for Mody, Type Iv

UniProtKB/Swiss-Prot : 71 Maturity-onset diabetes of the young 4: A form of diabetes that is characterized by an autosomal dominant mode of inheritance, onset in childhood or early adulthood (usually before 25 years of age), a primary defect in insulin secretion and frequent insulin-independence at the beginning of the disease.

MalaCards based summary : Mody, Type Iv, also known as mody4, is related to maturity-onset diabetes of the young and pancreatitis, and has symptoms including type ii diabetes mellitus and maturity-onset diabetes of the young. An important gene associated with Mody, Type Iv is PDX1 (Pancreatic And Duodenal Homeobox 1). The drugs Amlodipine and Valsartan have been mentioned in the context of this disorder. Affiliated tissues include endothelial, liver and bone.

Disease Ontology : 12 A maturity-onset diabetes of the young that has material basis in mutation in the PDX1 gene on chromosome 13q12.2.

Description from OMIM: 606392

Related Diseases for Mody, Type Iv

Diseases related to Mody, Type Iv via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 maturity-onset diabetes of the young 10.9
2 pancreatitis 9.9

Symptoms & Phenotypes for Mody, Type Iv

Clinical features from OMIM:

606392

Human phenotypes related to Mody, Type Iv:

32
id Description HPO Frequency HPO Source Accession
1 type ii diabetes mellitus 32 HP:0005978
2 maturity-onset diabetes of the young 32 HP:0004904

Drugs & Therapeutics for Mody, Type Iv

Drugs for Mody, Type Iv (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 238)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amlodipine Approved Phase 4 88150-42-9 2162
2
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
3
Fluvastatin Approved Phase 4 93957-54-1 1548972
4
Alogliptin Approved Phase 4,Phase 3,Phase 2,Phase 1 850649-61-5 11450633
5
Glimepiride Approved Phase 4,Phase 3,Phase 2,Phase 1 93479-97-1 3476
6
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1 657-24-9 14219 4091
7
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 111025-46-8 4829
8
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
9
Methyltestosterone Approved Phase 4 58-18-4 6010
10
Testosterone Approved, Investigational Phase 4 58-22-0 6013
11
Vildagliptin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 274901-16-5 6918537
12
Linagliptin Approved Phase 4,Phase 3,Phase 2,Phase 1 668270-12-0 10096344
13
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
14
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1 7440-66-6 32051 23994
15
Gliclazide Approved Phase 4,Phase 3,Phase 2 21187-98-4 3475
16
Ethanol Approved Phase 4 64-17-5 702
17
Voglibose Approved, Investigational Phase 4,Phase 3,Phase 2 83480-29-9 444020
18
Glipizide Approved Phase 4,Phase 3 29094-61-9 3478
19
Saxagliptin Approved Phase 4,Phase 3,Phase 2,Phase 1 361442-04-8 11243969
20
Insulin Glargine Approved Phase 4,Phase 3,Phase 1 160337-95-1
21
Insulin Lispro Approved Phase 4,Phase 3,Phase 2 133107-64-9
22
Oxymetazoline Approved Phase 4 1491-59-4 4636
23
Phenylephrine Approved Phase 4 59-42-7 6041
24
Glyburide Approved Phase 4,Phase 3 10238-21-8 3488
25
Acarbose Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 56180-94-0 441184
26
Liraglutide Approved Phase 4,Phase 3,Phase 1 204656-20-2 44147092
27
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
28
Insulin Aspart Approved Phase 4,Phase 3,Phase 2 116094-23-6 16132418
29
Repaglinide Approved, Investigational Phase 4 135062-02-1 65981
30
Insulin Detemir Approved Phase 4,Phase 3 169148-63-4 5311023
31
Exenatide Approved, Investigational Phase 4,Phase 3,Phase 1 141758-74-9 15991534
32 Lacidipine Approved Phase 4 103890-78-4
33
Rosiglitazone Approved, Investigational Phase 4,Phase 3,Phase 2 122320-73-4 77999
34
Insulin-glulisine Approved Phase 4 207748-29-6
35
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
36
Enalaprilat Approved Phase 4 76420-72-9 6917719
37
Nateglinide Approved, Investigational Phase 4,Phase 3 105816-04-4 60026
38
Empagliflozin Approved Phase 4,Phase 3,Phase 2 864070-44-0
39
Canagliflozin Approved Phase 4,Phase 3,Phase 2,Phase 1 842133-18-0
40
Adenosine Approved, Investigational Phase 4 58-61-7 60961
41
Regadenoson Approved Phase 4 313348-27-5 219024
42
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
43
Trandolapril Approved Phase 4 87679-37-6 5484727
44
Verapamil Approved Phase 4 52-53-9 2520
45
Nitric Oxide Approved Phase 4 10102-43-9 145068
46
Acetylcholine Approved Phase 4 51-84-3 187
47
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
48
Nitroprusside Approved Phase 4 15078-28-1 11963622
49
Guaifenesin Approved, Vet_approved Phase 4,Phase 2 93-14-1 3516
50
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635

Interventional clinical trials:

(show top 50) (show all 717)

id Name Status NCT ID Phase Drugs
1 Rationale and Design for Shiga Microalbuminuria Reduction Trial Unknown status NCT00202618 Phase 4 Valsartan;Amlodipine
2 The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion Unknown status NCT02406443 Phase 4 Sitaglitpin
3 Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension Unknown status NCT00407680 Phase 4 Intensive therapy Valsartan,Fluvastatin
4 Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin Unknown status NCT02426294 Phase 4 Pioglitazone;Glimepiride
5 Exploratory Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin (CGMS Study) Unknown status NCT02512523 Phase 4 Teneligliptin;Sitagliptin
6 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study) Unknown status NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo
7 Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism Unknown status NCT01084369 Phase 4 Testosterone
8 Effect of Dipeptidyl Peptidase-IV Inhibitor and Sulfonylurea on Glucose Variability and Oxidative Stress Unknown status NCT00699322 Phase 4 Sitagliptin;Glimepiride
9 Compare the Effect of DPP-IV Inhibitor or TZD on Glycemic Variability and Oxidative Stress in Patient With 2 Diabetes Unknown status NCT01339143 Phase 4 Galvus (vildagliptin);pioglitazone
10 Effect of Linagliptin on TRL Metabolism Unknown status NCT02280174 Phase 4 linagliptin
11 Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases Unknown status NCT01337440 Phase 4 UDCA;Sitagliptin
12 Syringes Replacement for Insulin Application for Pens Device in a Population of Elderly Patients With Type 2 Diabetes: Multifactorial Intervention to Improve Glycemic Control Unknown status NCT02517242 Phase 4
13 The Swiss Glucose Variability Study Unknown status NCT01426737 Phase 4 Vildagliptin
14 German Diabetes-Diet-Intervention and Energy Restriction-Trial (DDIET) Unknown status NCT01409330 Phase 4
15 Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02097342 Phase 4 Linagliptin;Placebo;Voglibose
16 Bone Turnover in Type 2 Diabetes Patients Unknown status NCT00732121 Phase 4 Sitagliptin;Placebo
17 Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia Unknown status NCT01267448 Phase 4 Glipizide XL;Saxagliptin + Metformin XR;Metformin XR
18 Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit Unknown status NCT02250794 Phase 4 metformin and sitagliptin;insulin glargine and insulin lispro;metformin and sitagliptin;insulin glargine and insulin lispro
19 Study of Comparing the Different Effect of DPP-4 Inhibitors and Sulfonylurea by Using "Biphase-Hyperglycemic Clamp" Unknown status NCT01660386 Phase 4 Sitagliptin;Saxagliptin;Glimepiride;Blank control
20 Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus Unknown status NCT01547104 Phase 4 Linagliptin;Glimepiride
21 Effects of Vildagliptin Versus Glibenclamide on Glycemia After Exercise in Patients With Type 2 Diabetes Unknown status NCT01867502 Phase 4 MET + Vildagliptin Group;MET + Glibenclamide Group
22 Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes Mellitus Unknown status NCT01206647 Phase 4 Metformin and Saxagliptin
23 Study on Exploring the Effect of DPP-4 Inhibitors on β-cell Function by Using the Two-step Hyperglycemic Clamp Unknown status NCT02386943 Phase 4 Sitagliptin;Saxagliptin;Blank control
24 Triple Therapy in Type 2 Diabetic Patients Unknown status NCT01895569 Phase 4 Metformin;Pioglitazone;Sitagliptin
25 Vascular Effects of Sitagliptin in Diabetes Mellitus Unknown status NCT01096277 Phase 4 Sitagliptin;Placebo
26 Efficacy and Safety of Lobeglitazone Versus Sitagliptin Unknown status NCT02480465 Phase 4 Lobelitazone 0.5mg;Sitagliptin 100mg
27 Saxagliptin's Effects on Microalbuminuria Improvement in Type 2 Diabetic Patients Unknown status NCT02462369 Phase 4 Saxagliptin;glimepiride
28 Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin. Completed NCT02157298 Phase 4 Dapagliflozin 5 mg;Placebo tablet
29 24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Contr Completed NCT02243176 Phase 4 Saxagliptin;Acarbose
30 DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes Completed NCT01472432 Phase 4 Placebo;vildagliptin
31 Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus Completed NCT02426541 Phase 4 Dapagliflozin;Placebo
32 A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients. Completed NCT02533453 Phase 4
33 The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes Completed NCT01181986 Phase 4 Exenatide SC;Exenatide IV;Placebo SC;Exendin-9;Placebo IV
34 Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin Completed NCT01766778 Phase 4 LAF237 (vildagliptin);Metformin
35 Efficacy and Tolerability of Saxagliptin add-on Compared to Uptitration of Metformin in Patients With Type 2 Diabetes Completed NCT01006590 Phase 4 Saxagliptin;Metformin
36 MASTERMIND - Understanding Individual Variation in Treatment Response in Type 2 Diabetes Completed NCT01847144 Phase 4 Gliclazide 80mg OD;Sitagliptin 100mg OD
37 Saxagliptin Compared to Glimepiride in Elderly Type 2 Diabetes Patients, With Inadequate Glycemic Control on Metformin Completed NCT01006603 Phase 4 Saxagliptin;Glimepiride
38 Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes Completed NCT02081599 Phase 4 Teneli (Teneligliptin);Placebo;Insulin
39 Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diabetes In Korea Completed NCT00328965 Phase 4 Lacidipine
40 Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea Completed NCT02471404 Phase 4 Dapagliflozin;Saxagliptin;Glimepiride;Placebo for dapagliflozin;Placebo for saxagliptin;Placebo for glimepiride
41 Efficacy of Pioglitazone in Patients With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy Completed NCT01972724 Phase 4 Pioglitazone
42 Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure Completed NCT01461577 Phase 4 INSULIN GLARGINE HOE 901
43 Pharmacokinetics Study of Dipeptidyl Peptidase 4 Inhibitor to Control Type 2 Diabetes Mellitus Completed NCT01449747 Phase 4 Sitagliptin
44 SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies Completed NCT01744236 Phase 4 Liraglutide;Sitagliptin;Exenatide;Liraglutide placebo;Sitagliptin placebo;Exenatide placebo;L-NMMA
45 Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications Completed NCT01107886 Phase 4 Saxagliptin;Placebo
46 Sitagliptin (DPP-4 Inhibitor) and NPH Insulin in Patients With T2D Completed NCT02607410 Phase 4 sitagliptin;NPH insulin
47 Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes Completed NCT01309698 Phase 4 Vildagliptin (LAF237);Voglibose;Vildagliptin and Voglibose
48 Evaluation of the Effectiveness and Safety of Physician Versus Patient-led of Insulin Glargine Initiation and Titration in Type 2 Diabetes Mellitus Completed NCT01169818 Phase 4 Insulin Glargine
49 Glibenclamide (Dose to be Titrated From Starting Dose of 5mg om) Plus Rosiglitazone 4mg om (Increased to 8mg om After 6 Months) and vs Glibenclamide (Dose to be Titrated With Starting Dose of 5mg om) Plus Placebo, Administered to Patients With Type 2 Diab Completed NCT01045590 Phase 4 titration;titration
50 Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure. Completed NCT01122979 Phase 4 INSULIN GLARGINE;NPH insulin (insulin isophane);INSULIN GLULISINE;Regular insulin

Search NIH Clinical Center for Mody, Type Iv

Genetic Tests for Mody, Type Iv

Genetic tests related to Mody, Type Iv:

id Genetic test Affiliating Genes
1 Maturity-Onset Diabetes of the Young, Type 4 29
2 Maturity-Onset Diabetes of the Young Type 4 24 PDX1

Anatomical Context for Mody, Type Iv

MalaCards organs/tissues related to Mody, Type Iv:

39
Endothelial, Liver, Bone, Heart, Testes, Kidney, Brain

Publications for Mody, Type Iv

Variations for Mody, Type Iv

UniProtKB/Swiss-Prot genetic disease variations for Mody, Type Iv:

71
id Symbol AA change Variation ID SNP ID
1 PDX1 p.Cys18Arg VAR_009309 rs137852785
2 PDX1 p.Gln59Leu VAR_009310 rs137852784
3 PDX1 p.Arg197His VAR_009312 rs137852786

ClinVar genetic disease variations for Mody, Type Iv:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 PDX1 PDX1, 1-BP DEL, 188C deletion Pathogenic
2 PDX1 NM_000209.3(PDX1): c.226G> A (p.Asp76Asn) single nucleotide variant risk factor rs137852783 GRCh37 Chromosome 13, 28494501: 28494501
3 PDX1 NM_000209.3(PDX1): c.188delC (p.Pro63Argfs) deletion Pathogenic rs193929377 GRCh37 Chromosome 13, 28494463: 28494463
4 PDX1 NM_000209.3(PDX1): c.533A> G (p.Glu178Gly) single nucleotide variant Pathogenic rs387906777 GRCh37 Chromosome 13, 28498519: 28498519
5 PDX1 NM_000209.3(PDX1): c.442C> G (p.Arg148Gly) single nucleotide variant Likely pathogenic rs193922355 GRCh37 Chromosome 13, 28498428: 28498428
6 PDX1 NM_000209.3(PDX1): c.571A> C (p.Lys191Gln) single nucleotide variant Likely pathogenic rs193922356 GRCh37 Chromosome 13, 28498557: 28498557
7 PDX1 NM_000209.3(PDX1): c.773A> G (p.Glu258Gly) single nucleotide variant Likely pathogenic rs193922360 GRCh37 Chromosome 13, 28498759: 28498759
8 PDX1 NM_000209.3(PDX1): c.502A> C (p.Asn168His) single nucleotide variant Likely pathogenic GRCh37 Chromosome 13, 28498488: 28498488

Expression for Mody, Type Iv

Search GEO for disease gene expression data for Mody, Type Iv.

Pathways for Mody, Type Iv

GO Terms for Mody, Type Iv

Sources for Mody, Type Iv

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....